City

Clinical trials near Porto Alegre, Brazil

Active studies with a listed research site in Porto Alegre, Brazil.

24active studies

15recruiting now

27countries represented

633largest site network

Current studies

Status and location data reflect the registry snapshot built 2026-09-08. Verify the original record before contacting a site.

Recruiting nowPhase 3

Efficacy and Safety of Orforglipron in Participants With Peripheral Artery Disease

Peripheral Arterial DiseaseCondition

Orforglipron, PlaceboTreatment

Argentina, Australia161 locations

Eli Lilly and CompanySponsor

Updated 2026-09-08 · NCT07223593See eligibility →

Recruiting nowPhase 3

A Study of Eloralintide (LY3841136) in Participants With Obstructive Sleep Apnea and Obesity or Overweight

Sleep Apnea, Obstructive, ObesityCondition

Eloralintide, PlaceboTreatment

Australia, Brazil115 locations

Eli Lilly and CompanySponsor

Updated 2026-09-08 · NCT07369011See eligibility →

Recruiting nowPhase 3

Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study

Ulcerative Colitis, Obesity or OverweightCondition

Mirikizumab, MirikizumabTreatment

Austria, Belgium187 locations

Eli Lilly and CompanySponsor

Updated 2026-09-04 · NCT06937086See eligibility →

Recruiting nowPhase 3

Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight

Crohn's Disease, Obesity or OverweightCondition

Mirikizumab, MirikizumabTreatment

Austria, Belgium183 locations

Eli Lilly and CompanySponsor

Updated 2026-09-04 · NCT06937099See eligibility →

Recruiting nowPhase 3

LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis

Metabolic Dysfunction Associated SteatohepatitisCondition

Survodutide, Placebo matching survodutideTreatment

Argentina, Australia445 locations

Boehringer IngelheimSponsor

Updated 2026-09-03 · NCT06632457See eligibility →

Recruiting nowPhase 3

A Study to Evaluate Effect of AZD6234 in Adult Participants With Obesity or Overweight With Weight-related Comorbidity Without Type 2 Diabetes Mellitus

Obesity or OverweightCondition

AZD6234, PlaceboTreatment

Argentina, Australia212 locations

AstraZenecaSponsor

Updated 2026-08-25 · NCT07784725See eligibility →

Recruiting nowPhase 3

A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes

Obesity, OverweightCondition

Eloralintide, PlaceboTreatment

Argentina, Australia162 locations

Eli Lilly and CompanySponsor

Updated 2026-08-21 · NCT07321886See eligibility →

Recruiting nowPhase 3

A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes

Obesity or OverweightCondition

Placebo, EnicepatideTreatment

Argentina, Australia195 locations

Hoffmann-La RocheSponsor

Updated 2026-08-14 · NCT07351045See eligibility →

Recruiting nowPhase 3

A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes

Obesity or Overweight, Type 2 Diabetes MellitusCondition

Placebo, EnicepatideTreatment

Argentina, Australia193 locations

Hoffmann-La RocheSponsor

Updated 2026-08-14 · NCT07351058See eligibility →

Recruiting nowPhase 3

Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea Not on Positive Airway Pressure (PAP) Therapy

Obstructive Sleep ApneaCondition

Maridebart cafraglutide, PlaceboTreatment

Australia, Brazil57 locations

AmgenSponsor

Updated 2026-08-14 · NCT07226765See eligibility →

Recruiting nowPhase 3

Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea on Positive Airway Pressure Therapy

Obesity, Obstructive Sleep ApneaCondition

Maridebart cafraglutide, PlaceboTreatment

Australia, Brazil61 locations

AmgenSponsor

Updated 2026-08-04 · NCT07225686See eligibility →

Recruiting nowPhase 3

A Study to Find Out if the Study Drug Elecoglipron Helps Adults With Type 2 Diabetes Mellitus by Comparing it With Semaglutide, a Medicine Already Used to Treat Type 2 Diabetes Mellitus

Type 2 Diabetes MellitusCondition

Elecoglipron, SemaglutideTreatment

Argentina, Australia201 locations

AstraZenecaSponsor

Updated 2026-07-14 · NCT07662213See eligibility →

Recruiting nowPhase 3

A Master Protocol to Investigate Efficacy and Safety of Elecoglipron in Participants With Obesity or Overweight With or Without T2DM

Weight ManagementCondition

Elecoglipron, PlaceboTreatment

Argentina, Australia321 locations

AstraZenecaSponsor

Updated 2026-07-10 · NCT07667803See eligibility →

Recruiting nowPhase 2

A Research Study Comparing How Well Different Doses of the Medicine NNC0519-0130 Can Reduce Kidney Damage in People Living With Chronic Kidney Disease

Chronic Kidney DiseaseCondition

NNC0519-0130, PlaceboTreatment

Argentina, Australia147 locations

Novo Nordisk A/SSponsor

Updated 2026-03-11 · NCT06717698See eligibility →

Recruiting nowNot applicable

Effect of Partial Dietary Replacement From Animal to Plant-Based Protein for Type 2 Diabetes Management

Type 2 Diabetes, OverweightCondition

Control Diet, Plant-based DietTreatment

Brazil1 locations

Hospital de Clinicas de Porto AlegreSponsor

Updated 2026-01-29 · NCT05706155See eligibility →

Opening soonPhase 3

A Study of Orforglipron (LY3502970) Compared With Dulaglutide in Pediatric Participants With Type 2 Diabetes

Diabetes Mellitus, Type 2Condition

Orforglipron, DulaglutideTreatment

Belgium, Brazil71 locations

Eli Lilly and CompanySponsor

Updated 2026-08-19 · NCT07668336See eligibility →

Opening soonPhase 3

A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in Children and Adolescents With Type 2 Diabetes

Diabetes Mellitus, Type 2Condition

CagriSema (Cagrilintide B and Semaglutide I), Placebo matched to CagriSema (Cagrilintide B and Semaglutide I)Treatment

Argentina, Brazil56 locations

Novo Nordisk A/SSponsor

Updated 2026-05-28 · NCT07282613See eligibility →

Opening soonPhase 3

AMAZE 8: A Research Study Investigating How Well the Medicine NNC0487-0111 Compared to Semaglutide Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight

Obesity, OverweightCondition

NNC0487-0111, SemaglutideTreatment

Argentina, Brazil120 locations

Novo Nordisk A/SSponsor

Updated 2026-03-12 · NCT07400107See eligibility →

Active, not recruitingPhase 3

Research Study on Whether Semaglutide Works in People With Non-alcoholic Steatohepatitis (NASH)

Non-alcoholic SteatohepatitisCondition

Semaglutide, PlaceboTreatment

Argentina, Australia558 locations

Novo Nordisk A/SSponsor

Updated 2026-09-04 · NCT04822181See eligibility →

Active, not recruitingPhase 3

REDEFINE 3: A Research Study to See the Effects of CagriSema in People Living With Diseases in the Heart and Blood Vessels

Cardiovascular DiseaseCondition

Cagrilintide, SemaglutideTreatment

Argentina, Australia633 locations

Novo Nordisk A/SSponsor

Updated 2026-08-31 · NCT05669755See eligibility →

Active, not recruitingPhase 3

A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities

Obesity, OverweightCondition

Orforglipron, PlaceboTreatment

Brazil, China138 locations

Eli Lilly and CompanySponsor

Updated 2026-08-14 · NCT05869903See eligibility →

Active, not recruitingNot applicable

Intervention Based on the Dietary Guidelines for the Brazilian Population for the Treatment of Overweight and Obesity

Obesity & Overweight, Overweight (BMI > 25)Condition

Collective Intervention Based on the Dietary Guidelines for the Brazilian Population, Control Group: Individualized CareTreatment

Brazil1 locations

Federal University of Health Science of Porto AlegreSponsor

Updated 2026-04-20 · NCT07538362See eligibility →

Active, not recruitingPhase 3

A Long-Term Study of Tirzepatide (LY3298176) in Adults With Type 1 Diabetes and Obesity or Overweight

Type 1 Diabetes, ObesityCondition

Tirzepatide, PlaceboTreatment

Argentina, Brazil79 locations

Eli Lilly and CompanySponsor

Updated 2026-02-17 · NCT06962280See eligibility →

Active, not recruitingPhase 3

A Master Protocol for Orforglipron in Participants With Obstructive Sleep Apnea and Obesity or Overweight

OSA, Overweight or ObesityCondition

Orforglipron, PlaceboTreatment

Argentina, Brazil66 locations

Eli Lilly and CompanySponsor

Updated 2025-09-29 · NCT06649045See eligibility →

How current is this page?

The page is rebuilt from the public registry feed. Each trial card shows the registry update date. Recruitment can still change between builds.

Does appearing here mean I qualify?

No. These pages are discovery indexes. Only a study team can confirm eligibility after reviewing the complete protocol criteria.

Clinical trials near Porto Alegre, Brazil

Current studies

Related cities